Community-based hearing aid fittings by community healthcare workers using smartphone-guided and pre-set devices in low- and middle-income communities.

Evaluating the Clinical Effectiveness of a Community-based Hearing Aid Fitting Service Delivery Model Facilitated by Community Healthcare Workers (CHWs) Providing Smartphone-based In-situ and Pre-set Hearing Aid Fittings in Low- and Middle-income Communities (LMICs)

Not applicable Interventional University of Pretoria · NCT06982716

This project will test whether community healthcare workers using smartphone-guided and pre-set hearing aid fittings help adults with mild-to-severe hearing loss in low- and middle-income communities hear better than minimal amplification.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment90 (estimated)
Ages18 Years and up
SexAll
SponsorUniversity of Pretoria Academic / other
Locations3 sites (Pretoria, Gauteng and 2 other locations)
Trial IDNCT06982716 on ClinicalTrials.gov

What this trial studies

This is a single-blind randomized controlled trial conducted in South African communities that compares smartphone-based in-situ (NAL-NL2) fittings and pre-set hearing aid fittings delivered by community healthcare workers (CHWs) against a minimal amplification control (flat 10 dB gain). Adults with bilateral mild-to-severe hearing loss (20 to <80 dB PTA) will be enrolled and randomized to one of the fitting approaches, using commercially available devices (Lexie Lumen, Go Ultra). Self-reported hearing benefits will be the primary outcome with follow-up visits at about 6 and 12 weeks to capture short-term outcomes and device usage. The design uses CHWs and mHealth tools to test a scalable, community-delivered service model in low- and middle-income settings.

Who should consider this trial

Good fit: Adults aged 18 and older with confirmed bilateral mild-to-severe hearing loss (20 to <80 dB PTA), no active middle ear disease, and willingness to attend 6- and 12-week follow-ups are ideal candidates.

Not a fit: People with very severe hearing loss (≥80 dB PTA), unilateral loss, active middle ear pathology, or those unable/unwilling to attend follow-ups are unlikely to benefit from this intervention.

Why it matters

Potential benefit: If successful, the approach could expand affordable, locally delivered, and effective hearing aid fittings that improve hearing and daily functioning for adults in low- and middle-income communities.

How similar studies have performed: Prior pilot studies and task-shifting/mHealth projects have shown promise for CHW-delivered and smartphone-guided hearing care, but randomized controlled evidence in low- and middle-income settings is still limited.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 18 years and older
* Confirmed mild to severe (20 to \< 80 dB PTA in both ears; (World Health Organization, 2021)) hearing loss (determined during baseline assessments)
* Willing/available to commit to at least 6- and 12-week follow-ups

Exclusion Criteria:

* Younger than 18 years
* Hearing loss too severe (≥80 dB HL PTA)
* Normal hearing (\<20 dB HL PTA)
* Middle ear pathology such as otitis media; active drainage from the ears.
* Unwilling/unavailable to commit to at least 6- and 12-week follow-ups.
* Unilateral hearing loss

Where this trial is running

Pretoria, Gauteng and 2 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Hearing Losshearing losscommunity-basedhearing aidservice delivery modelCommunity healthcare workersin-situpre-set hearing aids
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.